

May 2, 2023

Via Electronic Mail

Re: Exelixis' Policy Regarding Replenishment/Reclassification Requests


Dear 340B Covered Entity:

On behalf of Exelixis Inc. ("Exelixis"), I am writing to provide information about Exelixis' policy regarding requests by covered entities to replenish/reclassify prior purchases that were not made at the 340B ceiling price. Effective May 15, 2023, Exelixis will only honor requests for replenishment/reclassification that it receives within forty-five days of the date the product was dispensed.

Exelixis receives a significant volume of requests to replenish/reclassify at the 340B ceiling price product that was originally purchased and dispensed months, and sometimes years, prior. We are concerned that these lagged replenishment/reclassification requests complicate Exelixis' procedures for estimating sales and inventory and increase the risk of program integrity violations such as duplicate discounting. In addition, our two products—COMETRIQ[®] and CABOMETYX[®]—are sold in 30-count bottles. Based on typical prescribing and dispensing patterns, we expect that covered entities that dispense COMETRIQ[®] or CABOMETYX[®] will dispense a full bottle within a forty-five day period and thus can place associated replenishment orders within this timeframe.

Exelixis takes seriously our obligations under the 340B program, and we will continue to ensure that our covered outpatient drugs are available for purchase by 340B covered entities at the applicable statutory ceiling price. Please do not hesitate to contact 340B@exelixis.com if you have any questions.

Sincerely,



Darnell Turner

Executive Director, Government Pricing and Market Access Operations
Exelixis, Inc.